3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
108
Endometrial Neoplasms
16
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
9
Ovarian Neoplasms
7
Neoplasms
7
Advanced Breast Cancer
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Recurrence
3
Infertility
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Squamous Cell Carcinoma of Head and Neck
2
Progesterone Resistance
2
Neoplasms by Site
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Hyperplasia
2
Cystadenocarcinoma, Serous
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Breast Cancer Metastatic
2
Breast Cancer Female
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Letrozole
2
ribociclib
1
palbociclib
1
abemaciclib
1
Fulvestrant
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
HR+/HER2- Breast Cancer
×
Letrozole
×
1 year
×
Clear all
NCT07492641
2026-06-03
KANDELA-302
BeOne Medicines
Phase 3
Recruiting
1,056 enrolled
NCT06998407
2026-05-04
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2
Recruiting
380 enrolled